Amicus Therapeutics
Agent21Agent Readiness: 21/100. Bottom 25%. Measured by StartupHub.ai. Median 41.Trust92Data Trust: 92/100. Top 25%. Measured by StartupHub.ai. Median 61.Biotechnology company focused on developing treatments for rare metabolic diseases.
About
Amicus Therapeutics is a global biotechnology company focused on advancing therapies to treat rare diseases. As a wholly owned subsidiary of BioMarin Pharmaceutical Inc., it is guided by people living with rare diseases and aims to redefine expectations in this field. The company's website highlights its work in research and pipeline development, including clinical trials and expanded access programs for its medicines.
Similar companies
A biopharmaceutical company focused on developing and commercializing therapies for rare diseases.
Shares Rare Diseases, Drug Discovery
Clinical-stage biotech company developing AAV gene therapies for rare and retinal diseases.
Shares Biotech, MedTech
Biopharmaceutical company focused on developing and commercializing innovative treatments for rare neurological disorders.
Shares Biotech, MedTech
Clinical-stage biotechnology company developing Antibody Oligonucleotide Conjugates (AOCs) for serious diseases.
Shares Biotech, Drug Discovery
Biopharmaceutical company developing transformative therapies for rare metabolic diseases, focusing on hyperinsulinism.
Shares Biotech, MedTech
A clinical-stage biotechnology company developing transformative genome editing medicines for serious diseases.
Shares Biotech, MedTech
Key facts
- Website
- amicusrx.com
- Headquarters
- Philadelphia, United States
- Founded
- 2002
- Employees
- 625
- Total funding
- $200M (Series D)
- Business model
- B2B
Funding rounds
| Date | Round | Amount | Lead investors |
|---|---|---|---|
| 26 Jul 2007 | Series D | $100M | New Enterprise Associates |
| 29 Sept 2005 | Series C | $50M | Arch Venture Partners |
| 10 Mar 2004 | Series B | $30M | New Enterprise Associates |
| 23 Jan 2003 | Series A | $20M | SR One |
Tech stack
Detected on amicusrx.com, last scanned 30 Oct 2026. Run your own scan
- Frontend
- jQuery
- Analytics
- Google Analytics 4
- SEO
- Yoast SEO
- CMS / Builders
- WordPress
- Email provider
- Microsoft 365
- Cookie consent
- OneTrust
Test your Ahrefs DR
The backlink strength of a domain, on the Ahrefs 0 to 100 scale. About a minute.
Frequently asked
Is Amicus Therapeutics trustworthy and reputable?
StartupHub's Data Trust & Reputation score for Amicus Therapeutics is 92 out of 100, a trusted rating, based on site security posture, privacy practices, malware and phishing checks, and public reputation signals.
How much funding has Amicus Therapeutics raised?
Amicus Therapeutics has raised a total of $200M in funding. The most recent round on record is Series D.
How many employees does Amicus Therapeutics have?
Amicus Therapeutics has approximately 625 people on record.
SEC filings, insider activity, nonprofit links and pay benchmarks for Amicus Therapeutics:
Company details: from public sources. Funding: no announced round on file. Ownership: not yet claimed by the company. Scores: measured by named tools; each links to its method. Our rules
